Ennaliza Salazar

Dr. Ennaliza Salazar

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Digestive and Liver Disease
Verified
Journal Article
Closed access
WCWebber Chan
Webber Chan
ESEnnaliza Salazar
Ennaliza Salazar
TLTeong Guan Lim
Teong Guan Lim
WOWan Chee Ong
Wan Chee Ong
HSHang Hock Shim
Hang Hock Shim

15 June 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MQMartin Qui
Martin Qui
NBNina Le Bert
Nina Le Bert
WCWebber Pak Wo Chan
Webber Pak Wo Chan
MTMalcolm Tan
Malcolm Tan
SHShou Kit Hang
Shou Kit Hang
ESEnnaliza Salazar
Ennaliza Salazar
BACKGROUND. Patients undergoing immune-modifying therapies demonstrate a reduced humoral response after COVID-19 vaccination, but we lack a proper evaluation of the effect of such therapies on vaccine-induced T cell responses. METHODS. We longitudinally characterized humoral and spike-specific T cell responses in patients with inflammatory bowel disease (IBD), who were on antimetabolite therapy (azathioprine or methotrexate), TNF inhibitors, and/or other biologic treatment (anti-integrin or anti-p40) for up to 6 months after completing 2-dose COVID-19 mRNA vaccination. RESULTS. We demonstrate that a spike-specific T cell response was not only induced in treated patients with IBD at levels similar to those of healthy individuals, but also sustained at higher magnitude for up to 6 months after vaccination, particularly in those treated with TNF inhibitor therapy. Furthermore, the spike-specific T cell response in these patients was mainly preserved against mutations present in SARS-CoV-2 B.1.1.529 (Omicron) and characterized by a Th1/IL-10 cytokine profile. CONCLUSION. Despite the humoral response defects, patients under immune-modifying therapies demonstrated a favorable profile of vaccine-induced T cell responses that might still provide a layer of COVID-19 protection. FUNDING. This study was funded by the National Centre for Infectious Diseases (NCID) Catalyst Grant (FY2021ES) and the National Research Fund Competitive Research Programme (NRF-CRP25-2020-0003).

20 June 2023 in Nutrition
Verified
Journal Article
Closed access
JTJin Y.T. Tan
Jin Y.T. Tan
CCChang C.M. Cheah
Chang C.M. Cheah
YWYu T. Wang
Yu T. Wang
PCPik E.J. Chang
Pik E.J. Chang
TKThinesh Lee Krishnamoorthy
Thinesh Lee Krishnamoorthy
ESEnnaliza Salazar
Ennaliza Salazar

1 November 2018 in VideoGIE
Verified
Journal Article
Open access
ESEnnaliza Salazar
Ennaliza Salazar
ESEliza I. Sin
Eliza I. Sin
YLYee Low
Yee Low
CKChristopher J.L. Khor
Christopher J.L. Khor

1 February 2022 in Clinical Nutrition ESPEN
Verified
Journal Article
Closed access
RGRachel Jia Ling Goh
Rachel Jia Ling Goh
HLHuihua Li
Huihua Li
MCMark Chang Chuen Cheah
Mark Chang Chuen Cheah
ESEnnaliza Salazar
Ennaliza Salazar

1 September 2021 in Nutrition
Verified
Journal Article
Closed access
ESEnnaliza Salazar
Ennaliza Salazar
SASultan Alenezi
Sultan Alenezi
KSKatherine Schwenger
Katherine Schwenger
SCSarah Casselman
Sarah Casselman
NSNicha Somlaw
Nicha Somlaw
JAJohane Allard
Johane Allard